Form 4: Medpace CEO August J. Troendle Reports Sale of Common Stock

Medpace Holdings CEO August J. Troendle reported the sale of 4,956 shares of common stock at a weighted average price of $402.89 on May 10, 2024.

Summary

• On May 10, 2024, August J. Troendle, CEO of Medpace Holdings, Inc., sold 4,956 shares of common stock.
• The sale was executed at a weighted average price of $402.89 per share, with individual transactions ranging from $400.00 to $406.49.
• Following the transaction, Troendle directly owns 707,755 shares of Medpace Holdings, Inc.
• Troendle also indirectly owns 4,733,019 shares through Medpace Investors, LLC, where he serves as the sole manager and controlling unit holder.
• The sale was conducted pursuant to a limit order placed during an open window period.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports a transaction. It doesn't inherently indicate positive or negative outlook for the company.

Management Comments

• The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
• The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors regarding insider transactions.

Stakeholder Impact

• The stock sale by the CEO may be of interest to shareholders, potentially influencing their perception of the company's prospects.

Key Dates